Novoa Díaz MB, Gentili C, Martín MJ, Carriere P. Prognosis in stage II colon cancer: Expanding the horizons of risk factors. World J Gastrointest Oncol 2025; 17(2): 100552 [DOI: 10.4251/wjgo.v17.i2.100552]
Corresponding Author of This Article
María Julia Martín, PhD, Research Associate, Department of Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS)-INIBIBB (CONICET-UNS), Av La Carrindanga Km7, Bahía Blanca 8000, Buenos Aires, Argentina. julia.martin@uns.edu.ar
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 100552 Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100552
Prognosis in stage II colon cancer: Expanding the horizons of risk factors
María Belén Novoa Díaz, Claudia Gentili, María Julia Martín, Pedro Carriere
María Belén Novoa Díaz, Claudia Gentili, Pedro Carriere, Department of Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS)-INBIOSUR (CONICET-UNS), Bahía Blanca 8000, Buenos Aires, Argentina
María Julia Martín, Department of Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS)-INIBIBB (CONICET-UNS), Bahía Blanca 8000, Buenos Aires, Argentina
Author contributions: Novoa Díaz MB, Gentili C, Martín MJ and Carriere P contributed to this paper, the discussion, the writing, the design of the overall concept and outline of the manuscript, editing the manuscript, illustrations, and review of literature; all of the authors read and approved the final version of the manuscript to be published.
Supported by Consejo Nacional de Investigaciones Científicas y Técnicas, No. PIP11220200103061CO; Agencia Nacional de promoción Científica y Tecnológica, No. PICT-2020-SERIEA-03440; and Universidad Nacional del Sur, No. PGI 24/B303 and No. PGI 24/ZB01.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: María Julia Martín, PhD, Research Associate, Department of Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS)-INIBIBB (CONICET-UNS), Av La Carrindanga Km7, Bahía Blanca 8000, Buenos Aires, Argentina. julia.martin@uns.edu.ar
Received: August 19, 2024 Revised: October 31, 2024 Accepted: November 20, 2024 Published online: February 15, 2025 Processing time: 151 Days and 11.2 Hours
Abstract
In the following editorial, we discuss the article by Wu et al. In this contribution, we critically review the authors’ perspective and analyze the relevance of the results obtained in the original article of clinical research by Liu et al. We consider that additional factors associated with colon cancer progression have recently been described in extensive clinical research, and should be included in this analysis to achieve a more accurate prognosis. These factors include inflammation, gut microbiota composition, immune status and nutritional balance, as they influence the post-surgical survival profile of patients with stage II colorectal cancer. We also address the clinical implementation and limitations of these analyses. Evaluation of the patient´s entire context is essential for selection of the most appropriate therapy.
Core Tip: The treatment of patients with stage II colon cancer after surgical resection of the tumor is still under debate. Standard management based on the clinicopathological perspective is insufficient in cases not categorized as high-risk patients. Risk factors associated with the tumor and its microenvironment, including immune and inflammatory status, diet, and nutritional balance, should not be ruled out. The use of non-invasive molecular techniques to analyze these factors can provide relevant information for medical decisions in this group of patients.
